DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]
|
|
- Caitlin Lambert
- 6 years ago
- Views:
Transcription
1 SCREENING Visit Date: DEMOGRAPHICS / / [YYYY/MM/DD] Consent Signed Date and time / / [YYYY/MM/DD] : Has written assent been obtained? If no, why not? YES NO Gender: Male Female Birthdate: Permission given to store samples? / / [ YYYY/MM/DD] YES NO PHYSICAL ATTRIBUTES Height. cm t done Weight. kg t done Waist circumference First attempt Second attempt Average of 2 attempts. cm. cm. cm t done BMI. kg/m 2 t done VITAL SIGNS Heart Rate / Min t done Resp. Rate /Min t done Temperature. o C t done Sitting BP / t done Version: 01-Jun-2014 Completed by (initials): Page 1 of 28
2 SCREENING PHYSICAL EXAMINATION Body System Normal? Comment if not normal Head, Eyes, Ears, Nose, and Throat (HEENT) Respiratory Abdominal/ Gastrointestinal (GI) Pulmonary Cardiovascular Endocrine Musculoskeletal Neurologic/ Central Nervous System (CNS) Psychiatric Immunologic/ Allergy Gynecologic/ Urologic Other, specify: Version: 01-Jun-2014 Completed by (initials): Page 2 of 28
3 SCREENING RELEVANT HISTORY Has the subject ever been admitted to the hospital? Has the subject been diagnosed with a chronic disease? Has the subject been diagnosed with depression? Does the subject currently suffer from any allergies? Has the subject ever suffered from (or is currently suffering from) any other significant condition other than the study condition? If yes then please document on the medical history form. If yes then please document on the medical history form. If yes then please document on the medical history form. If yes then please document on the medical history form. If yes then please document on the medical history form. Any family history of Type 1 Diabetes? (1) Any family history of Type 1 Diabetes? (2) If yes, who: If yes, who: Any family history of Type 2 Diabetes? If yes, who: Any family history of Gestational Diabetes? Subject s Education Does the subject have a job? Some high school High school graduate/ged Some post-secondary school after graduation College, trade, technical, vocation or business diploma or certificate University Graduate Some graduate school Graduate degree If yes, who: Other: If yes, number of hours a week: Version: 01-Jun-2014 Completed by (initials): Page 3 of 28
4 SCREENING Any participation in any sports teams? Any other recreational exercise Does the subject smoke? Does the subject drink alcoholic beverages? Does the subject use recreational drugs? Are the subject s vaccinations up to date? Is the subject sexually active? If yes, number of hours a week: If yes, number of hours a week: If yes, number of cigarettes a week: If yes, number of beverages a week: If yes, number of times using a week: PREGNANCY TEST Is the subject female and of childbearing potential? Yes If male then answer no. If yes then perform a pregnancy test and complete the questions below. Date of test / / [YYYY/MM/DD] Result Negative Positive Version: 01-Jun-2014 Completed by (initials): Page 4 of 28
5 SCREENING MEDICAL HISTORY Does the participant/subject have a history of any medical problems/conditions? Yes If yes then document below. Use the following Body System codes: 1. Constitutional symptoms (e.g., fever, weight loss) 2. Eyes 3. Ears, Nose, Mouth, Throat 4. Cardiovascular Body System Code Medical History Term (One per line) 5. Respiratory 6. Gastrointestinal 7. Genitourinary 8. Musculoskeletal 9. Integumentary (skin and/or breast) Start Date [YYYY/MM/DD] 10. Neurological 11. Psychiatric 12. Endocrine 13. Hematologic/Lymphatic 14. Allergic/Immunologic Ongoing End Date [YYYY/MM/DD] Yes Yes Yes Yes Yes Yes Yes Version: 01-Jun-2014 Completed by (initials): Page 5 of 28
6 SCREENING CURRENT MEDICATIONS Did the subject take any medications within 30 days of study start? Yes Is the subject currently taking any medications? Yes If yes to either of these questions then please complete enter details on the Concomitant Medications form at the back of this CRF. INCLUSION CRITERIA Subjects must satisfy all of the following criteria years of age or older Yes 2. Signed informed consent Yes 3. Sexually active subjects willing to use acceptable method of contraception while participating in study 4. Male, or female and of child bearing potential with a negative pregnancy test at screening. Yes Yes 5. Willing and able to comply with all study procedures Yes EXCLUSION CRITERIA Subjects must have NONE of the following criteria 1. Female and breastfeeding at screening or planning on becoming pregnant at any time during the study. 2. Use of any investigational product or investigational medical device within 30 days prior to screening Yes Yes 3. Exclusion criteria 3 Yes 4. Exclusion criteria 4 Yes 5. Exclusion criteria 5 Yes Version: 01-Jun-2014 Completed by (initials): Page 6 of 28
7 SCREENING ELIGIBILITY Does the subject meet the conditions for enrollment into the study? Yes If the subject is eligible perform the randomization and write their treatment code below. Treatment Code NOTES AUTHORIZATION Principal Investigator Signature // Date [YYYY/MM/DD] Version: 01-Jun-2014 Completed by (initials): Page 7 of 28
8 BASELINE Visit Date: VITAL SIGNS / / [YYYY/MM/DD] Heart Rate / Min t done Resp. Rate /Min t done Temperature. o C t done Sitting BP / t done PHYSICAL EXAMINATION Body System Normal? Comment if not normal Head, Eyes, Ears, Nose, and Throat (HEENT) Respiratory Abdominal/ Gastrointestinal (GI) Pulmonary Cardiovascular Endocrine Musculoskeletal Neurologic/ Central Nervous System (CNS) Psychiatric Version: 01-Jun-2014 Completed by (initials): Page 8 of 28
9 BASELINE Immunologic/ Allergy Gynecologic/ Urologic Other, specify: BLOOD CHEMISTRY Date of test Is participant fasting? If fasting, time last eaten. t done / / [YYYY/MM/DD] Yes : (24 hour clock) Na K Cl TCO2 Ca Mg PO4 PTH Glucose Urea Creatinine Vitamin D Albumin T Protein Are any of these results clinically significant? mmol/l t Done. mmol/l t Done mmol/l t Done mmol/l t Done. mmol/l t Done. mmol/l t Done. mmol/l t Done ng/l t Done. mmol/l t Done. mmol/l t Done umol/l t Done nmol/l t Done g/l t Done g/l t Done Yes Version: 01-Jun-2014 Completed by (initials): Page 9 of 28
10 BASELINE If yes then please comment below. Comments: ADVERSE EVENTS / MEDICATIONS / DEVIATIONS Have there been any changes to the subject s medications since the last visit? Have there been any adverse events related to the study drug since the last study visit Has there been any protocol deviations reported related to this study visit? YES NO If yes, please complete an entry in the Concomitant Medications Log. YES NO If YES, please complete Adverse Event Log. YES NO If YES, please complete Protocol Deviation Log. MEDICATION ACCOUNTABILITY Treatment Code (Should match the code allocated at screening) Date distributed Bottle ID # Number of pills distributed / / [YYYY/MM/DD] Version: 01-Jun-2014 Completed by (initials): Page 10 of 28
11 BASELINE NOTES AUTHORIZATION Principal Investigator Signature // Date [YYYY/MM/DD] Version: 01-Jun-2014 Completed by (initials): Page 11 of 28
12 FOLLOW UP 1 Visit Date: VITAL SIGNS / / [YYYY/MM/DD] Heart Rate / Min t done Resp. Rate /Min t done Temperature. o C t done Sitting BP / t done PHYSICAL EXAMINATION Body System Normal? Comment if not normal Head, Eyes, Ears, Nose, and Throat (HEENT) Respiratory Abdominal/ Gastrointestinal (GI) Pulmonary Cardiovascular Endocrine Musculoskeletal Neurologic/ Central Nervous System (CNS) Psychiatric Version: 01-Jun-2014 Completed by (initials): Page 12 of 28
13 FOLLOW UP 1 Immunologic/ Allergy Gynecologic/ Urologic Other, specify: BLOOD CHEMISTRY Date of test Is participant fasting? If fasting, time last eaten. t done / / [YYYY/MM/DD] Yes : (24 hour clock) Na K Cl TCO2 Ca Mg PO4 PTH Glucose Urea Creatinine Vitamin D Albumin T Protein Are any of these results clinically significant? mmol/l t Done. mmol/l t Done mmol/l t Done mmol/l t Done. mmol/l t Done. mmol/l t Done. mmol/l t Done ng/l t Done. mmol/l t Done. mmol/l t Done umol/l t Done nmol/l t Done g/l t Done g/l t Done Yes Version: 01-Jun-2014 Completed by (initials): Page 13 of 28
14 FOLLOW UP 1 If yes then please comment below. Comments: ADVERSE EVENTS / MEDICATIONS / DEVIATIONS Have there been any changes to the subject s medications since the last visit? Have there been any adverse events related to the study drug since the last study visit Has there been any protocol deviations reported related to this study visit? YES NO If yes, please complete an entry in the Concomitant Medications Log. YES NO If YES, please complete Adverse Event Log. YES NO If YES, please complete Protocol Deviation Log. Version: 01-Jun-2014 Completed by (initials): Page 14 of 28
15 FOLLOW UP 1 MEDICATION ACCOUNTABILITY Did the subject return the unused medication? If yes, how many pills were returned? Please account for any unused medication: YES NO Was a new bottle of medication given to the study subject? Treatment Code YES NO If yes then please complete the details below. (Should match the code allocated at screening) Date distributed Bottle ID # Number of pills distributed / / [YYYY/MM/DD] NOTES AUTHORIZATION Principal Investigator Signature // Date [YYYY/MM/DD] Version: 01-Jun-2014 Completed by (initials): Page 15 of 28
16 FINAL FOLLOW UP 1 Visit Date: VITAL SIGNS / / [YYYY/MM/DD] Heart Rate / Min t done Resp. Rate /Min t done Temperature. o C t done Sitting BP / t done PHYSICAL EXAMINATION Body System Normal? Comment if not normal Head, Eyes, Ears, Nose, and Throat (HEENT) Respiratory Abdominal/ Gastrointestinal (GI) Pulmonary Cardiovascular Endocrine Musculoskeletal Neurologic/ Central Nervous System (CNS) Psychiatric Version: 01-Jun-2014 Completed by (initials): Page 16 of 28
17 FINAL FOLLOW UP 1 Immunologic/ Allergy Gynecologic/ Urologic Other, specify: BLOOD CHEMISTRY Date of test Is participant fasting? If fasting, time last eaten. t done / / [YYYY/MM/DD] Yes : (24 hour clock) Na K Cl TCO2 Ca Mg PO4 PTH Glucose Urea Creatinine Vitamin D Albumin T Protein Are any of these results clinically significant? mmol/l t Done. mmol/l t Done mmol/l t Done mmol/l t Done. mmol/l t Done. mmol/l t Done. mmol/l t Done ng/l t Done. mmol/l t Done. mmol/l t Done umol/l t Done nmol/l t Done g/l t Done g/l t Done Yes Version: 01-Jun-2014 Completed by (initials): Page 17 of 28
18 FINAL FOLLOW UP 1 If yes then please comment below. Comments: ADVERSE EVENTS / MEDICATIONS / DEVIATIONS Have there been any changes to the subject s medications since the last visit? Have there been any adverse events related to the study drug since the last study visit Has there been any protocol deviations reported related to this study visit? YES NO If yes, please complete an entry in the Concomitant Medications Log. YES NO If YES, please complete Adverse Event Log. YES NO If YES, please complete Protocol Deviation Log. MEDICATION ACCOUNTABILITY Did the subject return the unused medication? If yes, how many pills were returned? Please account for any unused medication: YES NO Version: 01-Jun-2014 Completed by (initials): Page 18 of 28
19 FINAL FOLLOW UP 1 NOTES AUTHORIZATION Principal Investigator Signature // Date [YYYY/MM/DD] Version: 01-Jun-2014 Completed by (initials): Page 19 of 28
20 STUDY COMPLETION Did the subject complete the study? If not, why not? Yes Lost to follow-up Withdrew consent Other (please comment) Adverse event n-compliance Comments: Date of discontinuation or completion. / / [YYYY/MM/DD] AUTHORIZATION Principal Investigator Signature // Date [YYYY/MM/DD] Version: 01-Jun-2014 Completed by (initials): Page 20 of 28
21 CONCOMITANT MEDICATIONS INSTRUCTIONS The Concomitant Medications form should be filled out at the screening visit and every study visit/time point thereafter. It may be helpful to ask study participants/subjects or their caregivers to bring prescription and over-the-counter medications to follow-up visits so that the medications can be more easily and accurately recorded on the CRF. Medication Name Record the verbatim name (generic or trade name) of the medication the participant/subject reports taking. See the data dictionary for additional information on coding the medication name using RXNorm. Indication Record the reason the participant/subject gives for taking the medication. If given for an AE, enter exact term from Adverse Event CRF. Dose Record the strength of the medication the participant/subject is taking. Dose Units - Record the units of the medication the participant/subject is taking. Frequency - Record how often the medication is being taken. Route Record the route of administration. Acceptable responses for Route are shown below the medication table. Start Date Record the date the participant/subject started taking the medication. The date should be recorded to the level of granularity known (e.g., year, year and month, complete date) and in the specified format to the study database. Start Date can be used to distinguish between prior medications and concomitant medications. Ongoing? Choose one. Answer YES if the participant/subject is still taking the medication or NO if the participant/subject has stopped taking the medication. End Date Record the date the participant/subject stopped taking the medication. The date/time should be recorded to the level of granularity known and in the specified format. End Date should be recorded if Ongoing is answered NO. Conversely, End Date should remain blank if Ongoing is answered YES. Version: 01-Jun-2014 Completed by (initials): Page 21 of 28
22 CONCOMITANT MEDICATIONS CONCOMITANT MEDICATIONS Medication Name Indication Dose Dose Unit Frequency Route Start Date [YYYY/MM/DD] Ongoing End Date [YYYY/MM/DD] Yes Yes Yes Yes Yes Yes Yes Version: 01-Jun-2014 Completed by (initials): Page 22 of 28
23 ADVERSE EVENTS ADVERSE EVENTS Adverse events (AEs) document medical events that occur to a participant/subject once enrolled in a study. AEs are the construct through which the safety of an intervention is recorded and assessed during a study. RECORDING ADVERSE EVENTS All AEs, both serious and non-serious, regardless of relationship to the study intervention, should be recorded on the AE case report form (CRF). AE data should be collected from the time the informed consent form is signed through the duration of the clinical investigation. Standard medical terminology should be used when recording AEs. SERIOUS ADVERSE EVENTS A serious adverse event is (SAE) defined as any untoward medical occurrence that at any dose results in one of the following outcomes: Death; A life-threatening adverse drug experience; Results in inpatient hospitalization or prolongation of existing hospitalization; A persistent or significant disability/incapacity; If an event is documented as serious, then a separate SAE Report form must completed. Because the data collected for an SAE are descriptive and beyond the scope of a study, the SAE information is usually kept in a separate file. SPECIFIC INSTRUCTIONS AE Description Any untoward medical occurrence in a study participant/subject that does not necessarily have a causal relationship with the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study intervention or study procedure, whether or not related to the study intervention or procedure. Each AE should be listed on a separate line. Any worsening of a baseline condition or reoccurrence of a baseline condition that had previously ended for a time should be listed as an AE. Events, such as nausea and vomiting are considered two events, and therefore should be listed on separate lines. A participant/subject may experience an unexpected AE. An unexpected adverse reaction has a nature or severity of which is not consistent with the study intervention description (e.g. Investigator's Brochure for an unapproved investigational product or package insert/summary of product characteristics for an approved product). The unexpected AE must be reported, whether related to the study intervention or not, with as much detail as is available Start Date Version: 01-Jun-2014 Completed by (initials): Page 23 of 28
24 ADVERSE EVENTS Record the date the adverse event started. The date should be recorded to the level of granularity known (e.g., year, year and month, complete date) and in the specified format. If a previously recorded AE worsens, a new record should be created with a new start date. There should be no AE start date prior to the date of the informed consent. Any AE that started prior to the informed consent date belongs instead in the medical history. If an item recorded on the medical history worsens during the study, the date of the worsening is entered as an AE with the start date as the date the condition worsened. End Date Record the date the adverse event stopped or worsened. The date should be recorded to the level of granularity known (e.g., year, year and month, complete date) and in the specified format. If an AE worsens, record an end date and create a new AE record with a new start date and severity. Severity Choose the one severity that best describes the investigator s assessment of the intensity of the AE. Severe events interrupt the participant s/subject s normal daily activities and generally require systemic drug therapy or other treatment; they are usually incapacitating. Consequently, a change in severity may constitute a new reportable AE. Severity is not synonymous with seriousness. A severe rash is not likely to be an SAE. Likewise, a severe headache is not necessarily an SAE. However, mild chest pain may result in a day s hospitalization and thus is an SAE. Relatedness Choose one. Record the investigator s assessment of the degree of relatedness of the AE to the study intervention.. Action Taken with Study Intervention Choose one. Other Action Taken Choose one. If treatment was required, then the corresponding treatment needs to be recorded on the Concomitant Medications CRF. Version: 01-Jun-2014 Completed by (initials): Page 24 of 28
25 ADVERSE EVENTS Outcome Choose one. The outcome of an AE may not be captured at the visit during which it was first reported, but must be captured to provide a complete picture of the event. Entering the outcome of an AE may be deferred until the AE is resolved, or the participant/subject completes the study. For AEs that have not resolved at the time of a study visit, the outcome should be marked as unresolved on the AE case report form. Serious Choose either Yes or No. This question should only be answered YES if the outcome of the AE results in at least one of the following: death; a life-threatening adverse drug experience; results in inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability/incapacity; or a congenital anomaly/birth defect. If an AE is serious, this provides a trigger that additional information must be provided by the site investigator. The site investigator then completes a Serious Adverse Event (SAE) form. Additionally, the site institution and/or IRB may also have an SAE form and procedures for reporting SAEs. Version: 01-Jun-2014 Completed by (initials): Page 25 of 28
26 ADVERSE EVENTS Adverse Event Start Date [YYYY/MM/DD] Severity Relatedness Action Taken with study intervention Other Action Taken Outcome Serious? End Date [YYYY/MM/DD] 1. Mild Unrelated ne ne Recovered/Resolved Yes* Moderate Severe Life-threatening or Disabling Fatal/Death Unlikely Probable Possible Definite Study Intervention Interrupted Study Intervention Discontinued Study Intervention Modified n-study Treatment Required Recovered/Resolved With Sequelae Recovering / Resolving Unresolved / Not Recovered Fatal Unknown 2. Mild Unrelated ne ne Recovered/Resolved Yes* Moderate Severe Life-threatening or Disabling Fatal/Death Unlikely Probable Possible Definite Study Intervention Interrupted Study Intervention Discontinued Study Intervention Modified n-study Treatment Required Recovered/Resolved With Sequelae Recovering / Resolving Unresolved / Not Recovered Fatal Unknown 3. Mild Unrelated ne ne Recovered/Resolved Yes* Moderate Severe Life-threatening or Disabling Fatal/Death Unlikely Probable Possible Definite Study Intervention Interrupted Study Intervention Discontinued Study Intervention Modified n-study Treatment Required Recovered/Resolved With Sequelae Recovering / Resolving Unresolved / Not Recovered Fatal Unknown * Yes should be answered when the adverse event results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. Principal Investigator Signature // Date [YYYY/MM/DD] Version: 01-Jun-2014 Completed by (initials): Page 26 of 28
27 PROTOCOL DEVIATIONS *DEVIATION CATEGORIES: A. Safety B. Informed Consent C. Eligibility D. Protocol implementation E. Other, specify in log **DEVIATION CODES: Numbers listed by the sample protocol deviations Safety (Category A) 1. Not reporting an SAE within 24 hours 2. Laboratory tests not done 3. AE/SAE is not reported to IRB 4. Other, specify in log Informed Consent (Category B) 5. Failure to obtain informed consent 6. Consent form used was not current IRB-approved version 7. Consent form does not include updates or information required by IRB 8. Consent form missing 9. Consent form not signed and dated by participant 10. Consent form does not contain all required signatures 11. Other, specify in log Eligibility (Category C) 12. Participant did not meet eligibility criterion 13. Randomization of an ineligible participant 14. Participant randomized prior to completing Baseline Assessment, etc. 15. Randomization and/or treatment of participant prior to IRB approval of protocol 16. Other, specify in log Protocol implementation (Category D) 17. Failure to keep IRB approval up to date 18. Participant receives wrong treatment 19. Participant seen outside visit window 20. Use of unallowable concomitant treatments 21. Prescribed dosing outside protocol guidelines 22. Missed assessment 23. Missed visit 24. Other, specify in log Version: 01-Jun-2014 Completed by (initials): Page 27 of 28
28 PROTOCOL DEVIATIONS Description of Protocol Deviation: Deviation Category* Deviation Code** Date Deviation Occurred: (yyyy/mm/dd) Date IRB Notified (if applicable): 1) 2) 3) 4) 5) Version: 01-Jun-2014 Completed by (initials): Page 28 of 28
Serious Adverse Event (SAE) Form Clinical Trials
Protocol Code number: LP0162-1334 1. Trial information: Subject ID: Site No.: Country: Is this the initial report of an SAE or a follow-up? Initial Follow-up, follow up no. In which period of the trial
More informationSerious Adverse Event (SAE) Form Clinical Trials
Protocol Code number: LP0162-1325 1. Trial information: Subject ID: Site No.: Country: If blinded trial, was the study treatment unblinded? Yes No Is this the initial report of an SAE or a follow-up? Initial
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationASSIGNED TREATMENT ARM
SF Radiation Therapy Oncology Group Phase III Lung High-dose vs Standard-dose Conformal XRT with Chemotherapy Consolidation Treatment Summary Form RTOG Study No. 0617 Case # AMENDED DATA YES INSTRUCTIONS:
More informationAdverse Experience Reporting
Managing and reporting adverse events Key learning objectives By the end of this session, you will be able to: Define and classify an adverse event; Differentiate between serious and severe adverse events;
More informationDear Mercy Cancer Center Radiation Oncology Patient
Dear Mercy Cancer Center Radiation Oncology Patient Welcome to our Department. In order to complete our records, and enable our physicians to ensure that your questions are fully addressed, we appreciate
More informationUnderstanding Adverse Events
The Fundamentals of International Clinical Research Workshop Understanding Adverse Events Deborah Hilgenberg Family Health International Goals of the Presentation Definition of Adverse Event (AE) Definitions
More informationSAE håndtering i protokol CC MM-001
SAE håndtering i protokol CC-92480-MM-001 An SAE is any AE occurring at any dose that: Results in death; Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate risk of
More informationSerious Adverse Event Report Form (CTIMP)
SAE Identifier: Serious Adverse Event Report Form (CTIMP) Form completion instructions overleaf 1. Report type (tick one) Initial report Follow-up information 2. Site name: 3. Participant details Study
More informationSAFETY AND EFFICACY ASSESSMENTS
SAFETY AND EFFICACY ASSESSMENTS The observations and procedures described in (Primary Arthritis Assessments) and the Hip or Knee Pain on motion assessment described in (Secondary Arthritis Assessment)
More informationGuideline Request Form Instructions
Guideline Instructions We at Office Ally realize that the process of creating Guidelines can be time consuming. In an effort to help speed up the process we have implemented a new solution. Now, instead
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSARAH VLACH, MD TYLER HEDIN, MD JUDY GOOCH, MD
Name: Height: Birthdate: Weight: Chief Complaint: What is the reason for your appointment? (please describe why you are here) Medications: Please list ALL medications with dosages you are currently taking,
More informationSeeing Chickens at Window Recording Adverse Events and GeneratingQuality Data. Margaret Band, Clinical Trial Manager, TCTU
Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data Margaret Band, Clinical Trial Manager, TCTU Adverse Event Reporting Monitoring of adverse events (AEs) is critical to the patient
More informationSouthern Maine Integrative Health Center Adult Intake Form
Southern Maine Integrative Health Center Adult Intake Form Patient Name: Address: Birthdate: / / Age: / / City: State/Zip: Home Telephone: ( ) Work Telephone: ( ) Employer: Cell phone: ( ) Email Address:
More informationHD CLINIC MEDICAL HISTORY FORM
HD CLINIC MEDICAL HISTORY FORM Welcome to the HDSA Center of Excellence HD Clinic. Please take a few moments to answer the questions below as best as you can. If you need assistance, a caregiver/companion
More informationSANTA MONICA BREAST CENTER INTAKE FORM
SANTA MONICA BREAST CENTER Who referred you to see us today? Who is your primary care physician? Are there any other MDs who you would like to receive today s visit information? No Yes MD contact info
More informationNew Patient Packet. Patient Name: DOB: Age: Address: City: State: Zip: Address: City: State: Zip: Name: Address: Phone: Fax:
New Patient Packet Patient Name: DOB: Age: Sex: Male / Female Height: Weight: PHYSICIAN CARE Primary Care Physician: Address: City: State: Zip: Phone: Fax: Referring Physician (if different from PCP):
More information8.0 ADVERSE EVENT HANDLING
8.0 ADVERSE EVENT HANDLING In accordance with the U.S. Code of Federal Regulations governing IND safety reports (Code of Federal Regulations 21, 312.32), adverse events (AEs) are reported from research
More informationGoal of site data management 12/2/2009. Ultimate goal: reliable and valid clinical trial to improve health
RC-4 Overview of Clinical Site Operations and Management Unit 4: Overview of Data Quality and Monitoring Principal Investigators Lynda Wilson, PhD, RN Marti Rice, PhD, RN Program Manager TBA Course Instructors:
More informationMAPS Study MT1 CRF Page 1. Baseline Evaluations: Record clinically significant findings on the Medical History CRF
MAPS Study MT1 CRF Page 1 Demographics Date of Screening - - dd mmm yyyy (may start up to one month prior to enrollment) Date of Birth: - - dd mmm yyyy Visit #1 Date of Enrollment - - dd mmm yyyy Sex:!
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationWELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Adverse Events in Clinical Trials: Definitions and Documentation May 2016 Objectives Recognize the
More informationEbele C. Chira, MD 1055 Clarksville Street, Suite 190, Paris, TX Phone (903) Fax (903)
Ebele C. Chira, MD 1055 Clarksville Street, Suite 190, Paris, TX 75460 Phone (903) 905-4609 Fax (903) 905-4611 Enclosed are forms for you to complete prior to your appointment. Please bring these completed
More informationadsm TB Version July 25 th, 2016
WHO central database for collection of safety data (AE and/or SAE) in the scope of adsm of anti-tb drugs Variables to be collected ID case number CONTR Case ID number Case identification number in national
More information68 Ga-DOTAXXX Template Case Report Forms (CRFs) Table of Contents
68 Ga-DOTAXXX Template Case Report Forms (CRFs) Table of Contents I. Screening Visit II. Imaging Baseline Visit III. Adverse Event (Baseline) IV. Image Interpretation Initial V. 24-hour Follow-Up Call
More informationManual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010
Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 January 2010 Version 2.0 Table of Contents 1. INTRODUCTION...1 1.1 Scope... 1 1.2 Purpose... 1 1.3 Responsibilities...
More informationChapter 8: Safety, Adverse Events and Endpoints
Table of Contents Chapter 8: Safety, Adverse Events and Endpoints... 8-1 8.1 The ACLAIMS Safety Officer... 8-1 8.2 Adverse Events (AE)... 8-1 8.3 Serious Adverse Events (SAEs)... 8-2 8.4 Classifying Adverse
More informationAdverse Event Monitoring and Reporting
Adverse Event Monitoring and Reporting MTN 005 Study-Specific Training SSP Section 11 AE Definition The International Conference on Harmonization Consolidated Guidance for Good Clinical Practice (ICH-E2A)
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationNEW PATIENT, UPDATE, OR HOSPITAL FOLLOW- UP NEUROLOGY QUESTIONNAIRE
Neurology East 48 Medical Park Dr. East Richard G. Diethelm, MD Suite 351 Andrea Sutton, RN, MSN, ANP- BC Birmingham, AL 35235 (205) 836-9366 www.neurologyeast.com NEW PATIENT, UPDATE, OR HOSPITAL FOLLOW-
More informationSafety Manual: DAD Trial
Safety Manual: DAD Trial Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial Short title: Diabetes and Depression
More informationDivision of AIDS Safety Office EXPEDITED ADVERSE EVENT (EAE) Form
To: DAIDS SAFETY OFFICE Division of AIDS Safety Office EXPEDITED ADVERSE EVENT (EAE) Form Sent by: Please type or print in English Fax: 1-800-275-7619 (USA) or + 1-301-897-1710 (International) Phone: 1-800-537-9979
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationINSTRUCTIONS: 1. Use codetable on page 1 for modifications / termination reasons
Radiation Therapy Oncology Group Phase III Head & Neck Cancer Treatment Summary Form AMENDED DATA YES INSTRUCTIONS: 1 Use codetable on page 1 for modifications / termination reasons SUMMARY OF SYSTEMIC
More informationTocilizumab/Roactemra Guided Questionnaire Anaphylaxis/Serious hypersensitivity reaction
Tocilizumab/Roactemra Guided Questionnaire Anaphylaxis/Serious hypersensitivity reaction AER: Site : Local Case ID: Patient Date of Birth Patient ID/Initials: Patient Gender: M F Tocilizumab (Actemra )
More informationPAGE 1 NEURO-OPHTHALMIC QUESTIONNAIRE NAME: AGE: DATE OF EXAM: CHART #: (Office Use Only)
PAGE 1 NEURO-OPHTHALMIC QUESTIONNAIRE NAME: AGE: DATE OF EXAM: CHART #: (Office Use Only) 1. What is the main problem that you are having? (If additional space is required, please use the back of this
More informationNEW PATIENT HEALTH HISTORY
NEW PATIENT HEALTH HISTORY Patient Name Today s Date Age Birth Date Date of last physical examination What is your reason for initial visit? Pharmacy Name & Telephone # NOTE: If you have prior records
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationName: Date: Referring Provider: What is the nature of your current gynecologic or urologic medical problem (use the other side if necessary).
Name: Date: Referring Provider: Age: D.O.B. Race/ ethnicity: What is the nature of your current gynecologic or urologic medical problem (use the other side if necessary). We are interested in learning
More informationPatient Information. First Name Middle Last Preferred Name. Street Address City State Postal Code
Ms. Patient Information First Name Middle Last Preferred Name Street Address City State Postal Code Work Phone ( ) Home Phone ( ) Cell Phone ( ) Email Preferred Contact Email Cell Home Work Emergency Contact
More informationPatient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio
927 W. Myrtle St. Boise, ID 83702 (208) 947-0100 NEW PATIENT INTAKE Patient Name: Date: Email Address: Primary Care Physician: How did you hear about AVT? (Please mark all that apply) Online Website On
More informationThe information you provide us will greatly help us provide the highest quality and most comprehensive care for you.
Rheumatology (circle location of appointment) 111 Hundertmark Rd. Suite 115N 560 S. Maple St. Suite 400 place patient label here Chaska, MN 55318 Waconia, MN 55387 952-361-2450 952-361-2450 The information
More informationUnanticipated Problems and Adverse Events
Unanticipated Problems and Adverse Events David Borasky, MPH, CIP Office of Research Protections RTI International Research Triangle Park, North Carolina, USA Introduction IEC review of unanticipated problems
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationREDDY & ASSOCIATES LLC D/B/A Reddy Medical Group D/B/A Reddy Urgent Care. Reddy Urgent Care Pre-Employment Physical Form
REDDY & ASSOCIATES LLC D/B/A Reddy Medical Group D/B/A Reddy Urgent Care 132 Franklin Springs St. 1061 Dowdy Road STE 100 280 General Daniels Ave. Royston, GA 30662 Athens, GA 30606 Danielsville, GA 30633
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationGASTROENTEROLOGY PATIENT QUESTIONNAIRE - PLEASE PRINT
GASTROENTEROLOGY PATIENT QUESTIONNAIRE - PLEASE PRINT Full name: Date: Telephone Number: Age: Address: Email address: CHIEF COMPLAINTS(List the problems about which you came to see the doctor) 1) 2) 3)
More informationPatient Medical History Form Pre-Surgical Bleeding History Questionnaire Name:
Patient Medical History Form Pre-Surgical Bleeding History Questionnaire Name: CIRCLE the appropriate response: Y yes or N no. A. Patient History 1. Has the patient ever had surgery, stitches for trauma
More informationTEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM
TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM PATIENT NAME: DATE OF BIRTH: TVA Physician being seen: Date of Visit: PAST MEDICAL HISTORY HEART PROBLEMS NEUROLOGICAL Congestive Heart Failure
More informationMCKAY UROLOGY LINCOLNTON OFFICE PATIENT HISTORY FORM
Patient name: MRN #: Current Medications (prescription and over the counter medications including vitamins, herbs, aspirin, antacids, injectables, hormones and birth control medication) If you brought
More informationADVERSE EVENT REPORTING. Catherine Dillon, CCRP
ADVERSE EVENT REPORTING Catherine Dillon, CCRP Reporting Adverse Events Adverse Events (AEs) are... any untoward medical occurrence in a subject that was not previously identified which does not necessarily
More informationLifestyle & Pre-diabetes Questionnaire
Please complete this questionnaire. The time you take to provide this information will help your health care team work better for you. General, Medical and Health Information Date: Name: Age: Race: Current
More informationColumbus Oncology and Hematology Associates 810 Jasonway Ave. Columbus, OH 43214, Ph: , Fax:
Columbus Oncology and Hematology Associates 810 Jasonway Ave. Columbus, OH 43214, www.coainc.cc Ph: 614.442.3130, Fax: 614.442.3145 Name (Last, First, Middle) Birth Date Age Social Security # Appointment
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationPlease have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in.
Please have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in. We have enclosed a questionnaire for you to complete and bring to the visit. Please
More informationAmarillo Surgical Group Doctor: Date:
Office Visit Information (General Surgery) Amarillo Surgical Group Doctor: Date: Patient s Information Name: Last First Middle Social Security #: Date of Birth: Age Gender: [ Male / Female ] Marital Status:
More informationWHI - Volume 3, Form 6 - Final Eligibility Assessment (Ver. 4) Page 1. Completed by Clinical Center (CC) staff; 2-page form; key-entered at CC.
WHI - Volume 3, Form 6 - Final Eligibility Assessment (Ver. 4) Page 1 FORM: 6 - FINAL ELIGIBILITY ASSESSMENT Version: 4 - June 1, 1995 Description: When used: Purpose: Completed by Clinical Center (CC)
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationWhere is your pain located? Please use the diagram below to indicate where most of your pain is located.
Name: Address: Social Security Number: Email Address: Emergency Contact: Primary Care Physician: Name: Address: Phone Number: Date of Birth: Today's date: Cell Phone Number: Phone #: Referring Physician:
More informationTocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events
Tocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events AER: Site : Local Case ID: Patient Date of Birth (dd-mmm-yyyy): Patient ID/Initials: Patient Gender: M F Patient Weight
More informationWELCOME TO OUR OFFICE
WELCOME TO OUR OFFICE Name: Today s Date: First Middle Last Gender: Male Female Date of birth: Age: Home Address: City: State: Zip: Home Phone:( ) Cell Phone:( ) Occupation: SSN: Employer: Time of employment
More informationPatient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code:
Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code: Date of Birth (MM/DD/YY): Social Security #: Sex: Male Female Home Phone #: Mobile Phone #: Email Address: Marital
More informationTOMBALL REGIONAL INTERNAL MEDICINE ASSOCIATES Medical Complex Drive, Suite 6 Tomball, TX
TOMBALL REGIONAL INTERNAL MEDICINE ASSOCIATES 13414 Medical Complex Drive, Suite 6 Tomball, TX 77375 281-516-0212 Welcome! We are glad that you have chosen Tomball Regional Internal Medicine Associates
More informationClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT)
ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT) January 9, 2009 * Required by ClinicalTrials.gov [*] Conditionally required by ClinicalTrials.gov (FDAAA) May be required to comply with
More informationGuidance on Unanticipated Problems (UPs) and Adverse Events (AEs) Bertha delanda IRB Training Specialist Research Compliance Office March 2010
Guidance on Unanticipated Problems (UPs) and Adverse Events (AEs) Bertha delanda IRB Training Specialist Research Compliance Office March 2010 OUTLINE - AE (adverse event) - SAE (serious adverse event)
More informationStudent Full Name: Date of Birth:
Student Medical Form This form is to be completed for new students upon admission, and returning students prior to starting grades 3, 6, and 9. Students participating in athletics must complete form every
More informationLogo Placement *######*
INPATIENT ADMITTING HISTORY AND PHYSICAL Page 1 of 8 Date of Service / / Time of Service : AM PM CHIEF COMPLAINT(S): HISTORY UNOBTAINABLE -- Patient was admitted UNACCOMPANIED, and no history could be
More informationMedical History Form
Medical History Form Name: ; Birth date: / / ; Date: / / Person filling out form: ; Relationship: Thank you for taking the time to fill out this valuable information. This allows us to provide the best
More informationWelcome to the Centre for Aging and Wellness at Florida Hospital!
133 Benmore Dr. Winter Park, FL 32789 PH: 407-599-6060 FAX: 407-646-7747 Welcome to the Centre for Aging and Wellness at Florida Hospital! We are pleased you have chosen us as part of your health care
More informationCECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)
IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:
More informationCenter for Advanced Wound Care New Patient Questionnaire Page 1 of 6
Center for Advanced Wound Care New Patient Questionnaire Page 1 of 6 These questions are general screening questions designed to identify areas where additional attention may be required. Please bring
More informationAllina Health United Lung and Sleep Clinic
Medical History Form Date Allina Health United Lung and Sleep Clinic Name Last First MI Date of birth What lung problem do you want us to help you with: Who is your primary care provider? Social History
More informationCompetencies and Objectives
Competencies and Objectives Chapter 1 EMS Systems Preparatory Emergency Medical Services (EMS) Systems Research Public Health Chapter 2 Workforce Safety and Wellness Medicine Infectious Diseases Preparatory
More informationHEALTH EXAMINATION GUIDELINES FOR ENTRY INTO MALAYSIAN HIGHER EDUCATIONAL INSTITUTIONS
HEALTH EXAMINATION GUIDELINES FOR ENTRY INTO MALAYSIAN HIGHER EDUCATIONAL INSTITUTIONS LAMPIRAN A 1. PLEASE READ THE INSTRUCTIONS CAREFULLY BEFORE FILLING IN THE FORM. 2. PLEASE FILL IN THE FORM IN ENGLISH
More informationNew Patient Questionnaire Pediatric Orthopaedic Surgery
Page 1 of 5 New Patient Questionnaire Pediatric Orthopaedic Surgery First Name: Last Name: Middle: DOB: Height: Weight: Primary Care Physician/Pediatrician Name: Address: Phone Number: Chief Compliant
More informationAdverse Events- Love them, hate them, report them!
Adverse Events- Love them, hate them, report them! Billi Tatum, RN, CCRC Regional Vascular Center Harborview Medical Center and the University of Washington Medical Center Objectives Define and identify
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More informationA. Please include any medications (herbal, prescription, or Over-the-counter) and any supplements that you are currently taking.
New Patient Questionnaire Please complete this and bring it with you to your visit. If you have it completed five days or more prior to your visit, please mail or fax it to our office. Most recent treating
More informationCOMPREHENSIVE NEW PATIENT QUESTIONNAIRE
What brings you in today? What do you prefer to be called (nickname)? Please list all of your medical conditions. 1. 5. 2. 6. 3. 7. 4. 8. What surgical or medical procedures have you had in the past? 1.
More informationPediatric Case History Form
Pediatric Case History Form Patient s full name: Date of completion: Date of birth: Gender (circle one): Male Female Mother s full name: Father s full name: Legal guardian s full name(s): Person completing
More informationDeveloping a Detection and Reporting System for Adverse Events. Deborah Hilgenberg Family Health International
Developing a Detection and Reporting System for Adverse Events Deborah Hilgenberg Family Health International Elements of Reporting Detection System Written definition of adverse events Checklist of expected
More informationSilver Child Development Center New Patient Questionnaire. Relation (circle) Biological Mother Stepmother Adoptive Mother
Silver Child Development Center New Patient Questionnaire Today s Date Mother s Name First Last Date of Birth Relation (circle) Biological Mother Stepmother Adoptive Mother Foster Mother Other Father s
More informationHEALTH EXAMINATION GUIDELINES FOR ENTRY INTO MALAYSIAN HIGHER EDUCATIONAL INSTITUTIONS
LAMPIRAN A HEALTH EXAMINATION GUIDELINES FOR ENTRY INTO MALAYSIAN HIGHER EDUCATIONAL INSTITUTIONS 1. PLEASE READ THE INSTRUCTIONS CAREFULLY BEFORE FILLING IN THE FORM. 2. PLEASE FILL IN THE FORM IN ENGLISH
More informationOB/GYN COMPREHENSIVE PATIENT INTAKE HISTORY
FOR OFFICE USE ONLY NEW PATIENT ESTABLISHED PATIENT CONSULTATION REPORT SENT: / / OB/GYN COMPREHENSIVE PATIENT INTAKE HISTORY PATIENT NAME: AGE: BIRTHDATE / / DATE: / / RACE: CAUCASIAN AFRICAN-AMERICAN
More informationPatient Medical Information. Last. Sex: M / F Age: Date of Birth: Home Address: City: State: Zip Code: Business Address: City: State: Zip Code:
Patient Medical Information Name: First Middle Last Sex: M / F Age: Date of Birth: Social Security # Driver s License # Home Address: City: State: Zip Code: Home Phone: Occupation: Cell: Employer: Business
More informationPRE-OP SHORT HISTORY & PHYSICAL
PRE-OP SHORT HISTORY & PHYSICAL Rev 4/16 First Name Last Name Medical History and Health Information: These uestions are for your benefit and assure that your past and present health status will be taken
More informationWELCOME TO COPPELL VISION CENTER 541 E. Sandy Lake Road, Coppell, Texas (972) Personal Information
WELCOME TO COPPELL VISION CENTER 541 E. Sandy Lake Road, Coppell, Texas 75019 (972) 393-3937 (Please Print Clearly) Personal Information Last Name: First Name: Exam Date: / / Street Address: City/State/Zip:
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPATIENT HISTORY FORMS FOR OUTPATIENT CONSULTATION
PATIENT HISTORY FORMS FOR OUTPATIENT CONSULTATION Patient Instructions: Fill out all other forms including this one to get you registered. Print this one out and then go to forms to get your financial
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationHistory of Present Illness Please answer the following questions
Last Name First Name Date of Birth: / / What is the main reason for your visit today? Social Security Number: History of Present Illness Please answer the following questions Bladder Cancer Urinary Tract
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationFactorial Study Design 07/18/12
Disclaimer: The following information is fictional and is only intended for the purposes of illustrating key concepts for results data entry in the Protocol Registration System (PRS). Example Factorial
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationToday s Date: Pt Initials: PATIENT INFORMATION. First Name: Last Name: Middle Name: Date of Birth: Social Security #: Preferred Language:
PATIENT INFORMATION First Name: Last Name: Middle Name: Suffix: Nickname: Male Female Date of Birth: Social Security #: Preferred Language: Race: Asian Native Hawaiian Other Pacific Islander Black / African
More informationPatient Name Date of Birth Page 1 of 6
2545 W. Hillcrest Dr. #205 Thousand Oaks, CA 91320 Admissions: 888.822.8938 Fax: 805.273.5246 Dear Medical Professional, This patient is seeking care to address eating disorder behaviors. For the patient
More information